# Feasibility Assessment: Neuronal Autophagy Resistance Mechanisms in ALS
## Executive Summary
Of the five proposed hypotheses, the SKEPTIC's critical evaluation substantially weakens three (H1, H2, H5) through mechanistic confounds and non-uniqueness arguments. Two mechanisms (H3, H4) survive rigorous critique and warrant prioritized investigation, though each faces distinct clinical development obstacles.
---
## Hypothesis 1: mTORC1-TFEB/TFE3 Axis
**Survival Status: Questionable**
**Revised Confidence: 0.45-0.50** (post-SKEPTIC downgrade to 0.58 appears optimistic)
### Druggability: MODERATE
| Modality | Examples | BBB Penetration | Clinical Stage |
|----------|----------|-----------------|----------------|
| mTORC1 inhibitors | Rapamycin, Everolimus, Torkinib | Poor-moderate | Approved (other indications) |
| TFEB activators | Small molecules (un-named) | Unknown | Preclinical |
| Combination | mTORi + lysosomal boosters | Variable | Exploratory |
**Core Problem:** Drugging mTORC1 to activate TFEB assumes TFEB nuclear translocation is rate-limiting. If downstream lysosomal acidification (H3) is the true bottleneck, mTOR inhibitors will show autophagic flux improvement on canonical readouts (LC3-II, p62 turnover) without functional benefit—explaining the "attenuated neuronal response" without establishing causality.
### Biomarkers & Model Systems: ROBUST
- **Readouts:** Nuclear:cytoplasmic TFEB ratio (confocal microscopy), CLEAR gene panel (qPCR), p-S6K1 S240/244
- **Model Systems:** FANN-isolated motor neuron nuclei (SOD1G93A) are technically feasible; iPSC-derived motor neurons with TFEB-GFP reporters are well-established
- **Falsifying Experiment Feasibility:** AAV delivery of constitutively nuclear TFEB (S211A/S122A) to spinal cord motor neurons is achievable within 18 months
### Clinical Development Constraints: SIGNIFICANT
- **Indication alignment:** Chronic ALS treatment requires sustained dosing; rapamycin analogues carry metabolic and immunosuppressive burden incompatible with ALS patient population
- **Target engagement assays:** No validated human TFEB nuclear translocation biomarker exists for CSF or blood
- **Patient stratification:** No genomic marker identifies which patients have mTORC1 hyperactivation vs. downstream blocks
### Safety: CONCERNING
| Risk | Severity | Monitoring Requirement |
|------|----------|------------------------|
| Immunosuppression | High | CBC, infection surveillance |
| Metabolic dysfunction | Moderate | Glucose, lipid panels |
| Off-target lysosomal inhibition | Moderate | Tissue-specific acidification assays |
### Timeline/Cost: REALISTIC FOR REPURPOSING
- **Repurposing pathway:** 3-4 years to Phase 2 (existing safety data)
- **De novo development:** 7-9 years for novel TFEB activators
- **Estimated cost:** $15-30M (repurposing) / $80-120M (de novo)
**Recommendation:** Perform falsifying experiment with constitutively nuclear TFEB before committing resources. If flux remains impaired, deprioritize.
---
## Hypothesis 2: PP2A/Bβ1 Targeting ULK1
**Survival Status: Weak**
**Revised Confidence: 0.40-0.50**
### Druggability: LOW-MODERATE
**Critical Gap:** The hypothesis lacks mechanistic specificity for how PP2A-Bβ1 discriminates ULK1-S757 over S317. Without structural data on the PP2A-Bβ1:ULK1 interface, rational drug design is impossible.
| Approach | Feasibility | Gap |
|----------|-------------|-----|
| Pan-PP2A inhibitors (LB-100) | Achievable | Lacks neuronal Bβ1 selectivity; cross-tissue toxicity |
| Bβ1-selective compounds | Requires structural biology first | No structural data on Bβ1 regulatory subunit binding |
| CRISPRi PPP2R2B | Technically feasible | Not druggable for chronic ALS treatment |
### Biomarkers & Model Systems: MODERATE
- **Phospho-ULK1 S757:** Phospho-specific antibodies exist; technically quantifiable
- **PP2A-Bβ1 interaction with ULK1:** Requires IP-mass spectrometry validation (proposed experiment is sound)
- **Model systems:** iPSC-derived motor neurons suitable; fibroblasts as controls
### Clinical Development Constraints: HIGH
- **Specificity problem:** PPP2R2B is "neuron-enriched" not "neuron-exclusive." Non-neuronal cells expressing this subunit should show similar resistance if this is primary—yet rapamycin induces autophagy in hepatocytes.
- **Mechanistic ambiguity:** Whether AMPK activators work in neurons depends on whether they bypass PP2A-Bβ1 (via S317) or overcome it (via unclear compensation). The cited evidence does not resolve this.
- **Target validation sequencing:** Must confirm structural interface before clinical investment
### Safety: UNCERTAIN
LB-100 shows acceptable safety in oncology trials, but:
- PP2A has broad substrates beyond ULK1
- Neuronal PP2A regulates synaptic proteins (PPP2R2A, not Bβ1, but isoform specificity unclear)
- Long-term safety in CNS application untested
### Timeline/Cost: HIGH RISK
- **6-8 years